natalizumab
Selected indexed studies
- Natalizumab. (Drugs Today (Barc), 2006) [PMID:17136224]
- PB006: A Natalizumab Biosimilar. (Clin Drug Investig, 2024) [PMID:38683493]
- A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. (N Engl J Med, 2006) [PMID:16510744]
_Worker-drafted node — pending editorial review._
Connections
natalizumab is a side effect of
Sources
- Natalizumab. (2006) pubmed
- PB006: A Natalizumab Biosimilar. (2024) pubmed
- A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. (2006) pubmed
- Natalizumab update. (2007) pubmed
- Natalizumab-induced pneumonitis. (2022) pubmed
- Natalizumab in Multiple Sclerosis: Long-Term Management. (2017) pubmed
- Use of natalizumab in persons with multiple sclerosis: 2022 update. (2022) pubmed
- Natalizumab-Associated Primary Central Nervous System Lymphoma. (2018) pubmed
- Natalizumab for GVHD: too little or too late? (2023) pubmed
- Natalizumab exposure during pregnancy in multiple sclerosis: a systematic review. (2019) pubmed